(Q37368688)

20 August 2017

1 reference

title

Current pharmacotherapeutic concepts for the treatment of obesity in adults (English)

1 reference

20 August 2017

0 references

Evgeny Idelevich

1

1 reference

20 August 2017

Wilhelm Kirch

series ordinal

2

1 reference

20 August 2017

Christoph Schindler

series ordinal

3

1 reference

20 August 2017

publication date

28 November 2008

1 reference

Therapeutic advances in cardiovascular disease

20 August 2017

published in

1 reference

20 August 2017

volume

3

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

75-90

1 reference

The efficacy and safety of sibutramine for weight loss: a systematic review

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The obesity epidemic: pharmacological challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Drug treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Opportunities and challenges for the development of pharmacological therapies for obesity treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Rimonabant for overweight or obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Years of life lost due to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Orlistat and sibutramine beyond weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effects of orlistat on fat-soluble vitamins in obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Orlistat inhibits dietary cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Long-term pharmacotherapy for obesity and overweight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Pharmacological therapy of obesity: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Orlistat over the counter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

Recognition and management of overweight and obesity in primary care in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944708098226

21 January 2018

Identifiers

DOI

10.1177/1753944708098226

1 reference

20 August 2017

1 reference